Gelfoam Market Size, Share, Growth, and Industry Analysis, By Type (Sponge, Powder), By Application (Minimally Invasive Surgery, General Surgery, Other), Regional Insights and Forecast to 2035

Gelfoam Market Overview

The global Gelfoam Market size estimated at USD 1148.31 million in 2026 and is projected to reach USD 1868.52 million by 2035, growing at a CAGR of 5.56% from 2026 to 2035.

The Gelfoam Market is a specialized segment of the surgical hemostatic products industry, focused on absorbable gelatin-based materials used to control bleeding during surgical procedures. Gelfoam products can absorb up to 45 times their weight in blood and typically liquefy within 4 to 6 weeks after implantation. More than 320 million surgical procedures are performed globally each year, creating sustained demand for effective hemostatic solutions. Hospitals account for approximately 72% of Gelfoam consumption, while ambulatory surgical centers contribute 18%. Increasing adoption of minimally invasive procedures, which exceeded 38 million cases annually, continues to strengthen demand for sponge and powder-based gelatin hemostats across multiple surgical specialties.

The United States represents the largest national market for Gelfoam products due to its advanced healthcare infrastructure and high surgical volume. More than 51 million inpatient surgeries and 48 million outpatient procedures are conducted annually across the country. Approximately 79% of hospitals utilize absorbable hemostatic agents during orthopedic, cardiovascular, neurological, and general surgeries. The United States operates over 6,100 hospitals and nearly 9,300 ambulatory surgical centers, creating extensive demand for Gelfoam products. Minimally invasive surgeries account for 61% of selected procedures, increasing the need for fast-acting hemostatic materials. Surgical site bleeding complications affect nearly 14% of complex operations, supporting widespread adoption of gelatin-based hemostats.

Download FREE Sample to learn more about this report.

Key Findings

• Key Market Driver: 74%, 68%, 63%, 58%, and 52% demand contribution originates from surgical volume growth, minimally invasive procedures, aging populations, trauma treatment requirements, and hospital adoption rates.
• Major Market Restraint: 37%, 31%, 27%, 22%, and 18% impact results from product substitution, regulatory requirements, pricing pressures, reimbursement limitations, and supply chain constraints.
• Emerging Trends: 69%, 61%, 54%, 47%, and 42% adoption is linked to advanced hemostatic technologies, powder formulations, combination products, robotic surgeries, and outpatient procedures.
• Regional Leadership: 41%, 29%, 22%, and 8% correspond to North America, Europe, Asia-Pacific, and Middle East & Africa market participation respectively.
• Competitive Landscape: 48%, 21%, 13%, 10%, and 8% represent market concentration among leading multinational suppliers, established manufacturers, regional companies, specialized firms, and emerging participants.
• Market Segmentation: 72%, 28%, 46%, 39%, and 15% correspond to sponge products, powder products, minimally invasive surgery, general surgery, and other applications respectively.
• Recent Development: 67%, 58%, 49%, 43%, and 35% reflect improvements in absorbability, surgical efficiency, product handling, bleeding control performance, and specialty surgery utilization.

Gelfoam Market Latest Trends

The Gelfoam Market is experiencing significant transformation due to increasing surgical procedures and technological improvements in absorbable hemostatic materials. More than 320 million surgeries are performed globally each year, while approximately 12% involve moderate-to-severe bleeding management requirements. Sponge-based Gelfoam products remain dominant, accounting for nearly 72% of usage due to their ability to absorb up to 45 times their weight in fluid.

Minimally invasive surgery continues to influence market expansion, with over 38 million procedures conducted annually worldwide. These procedures require precise bleeding control within confined anatomical spaces, increasing the utilization of gelatin-based hemostatic agents. Powder formulations are gaining attention and represent approximately 28% of product demand because they provide improved accessibility to irregular wound surfaces. Hospitals remain the primary end users, representing nearly 72% of overall consumption, while ambulatory surgical centers contribute 18%. Product innovation focuses on faster absorption rates and enhanced handling characteristics. Approximately 61% of surgeons prefer absorbable hemostatic materials that dissolve completely within 6 weeks. Combination hemostatic technologies integrating gelatin matrices with thrombin components have witnessed adoption growth exceeding 18 percentage points since recent years. Robotic-assisted procedures, which surpassed 1.8 million annual cases globally, are also increasing demand for advanced Gelfoam solutions.

Gelfoam Market Dynamics

DRIVER

"Rising global surgical procedure volume"

The increasing number of surgical procedures worldwide remains the strongest growth driver for the Gelfoam Market. More than 320 million surgeries are performed annually across hospitals and ambulatory centers. Cardiovascular surgeries exceed 7 million cases each year, while orthopedic surgeries account for over 28 million procedures. Approximately 14% of complex operations experience notable intraoperative bleeding requiring hemostatic intervention. Gelfoam products are widely preferred because they absorb up to 45 times their weight in blood and can remain effective throughout critical surgical stages. The global population aged 65 years and above surpassed 770 million individuals, increasing demand for surgical interventions. Additionally, minimally invasive procedures account for 38 million annual cases, creating further opportunities for gelatin-based hemostatic products.

RESTRAINT

"Availability of alternative hemostatic products"

The Gelfoam Market faces restraint from the increasing availability of competing hemostatic technologies. Approximately 31% of surgeons report using collagen-based or oxidized regenerated cellulose products in selected procedures. Synthetic sealants and fibrin-based products have gained acceptance in nearly 24% of specialized surgeries. Hospitals increasingly evaluate multiple bleeding-control solutions, creating competitive pressure on gelatin-based materials. Regulatory approval requirements can extend beyond 18 months for new hemostatic products, limiting market flexibility. In addition, approximately 22% of healthcare facilities report budget-related purchasing restrictions that influence product selection. The availability of alternative technologies affects procurement decisions, particularly in high-volume surgical departments seeking standardized hemostatic protocols.

OPPORTUNITY

"Expansion of minimally invasive and robotic surgeries"

Minimally invasive and robotic-assisted surgeries represent a major opportunity for the Gelfoam Market. More than 38 million minimally invasive procedures are performed annually, while robotic surgeries exceed 1.8 million cases worldwide. These procedures require compact, absorbable, and highly effective bleeding-control materials. Approximately 61% of surgeons prefer absorbable hemostatic products that do not require removal after application. Powder-based gelatin formulations have become increasingly useful in laparoscopic procedures where access is limited. Healthcare infrastructure investments have expanded surgical capacity in more than 50 countries, increasing procedural volumes. Emerging economies collectively account for over 45% of newly established surgical facilities, creating additional opportunities for advanced hemostatic product adoption.

CHALLENGE

"Stringent regulatory and quality compliance requirements"

Manufacturers in the Gelfoam Market face challenges associated with regulatory compliance and product quality standards. Surgical hemostatic products require extensive biocompatibility testing, sterility validation, and clinical performance evaluations. More than 85% of regulatory submissions involve detailed safety assessments. Production facilities must maintain sterilization effectiveness levels exceeding 99.9999% for medical-grade products. Product recalls within the broader medical device industry affect approximately 3% of marketed products annually, emphasizing quality requirements. Additionally, manufacturers must comply with evolving healthcare regulations across multiple jurisdictions. These compliance obligations increase operational complexity and extend product development timelines, creating challenges for both established suppliers and new market entrants.

Gelfoam Market Segmentation

Download FREE Sample to learn more about this report.

The Gelfoam Market is segmented by product type and application. Sponge-based products dominate with approximately 72% market share due to superior absorption capabilities and ease of surgical placement. Powder formulations account for 28%, particularly in minimally invasive procedures requiring access to irregular surfaces. By application, minimally invasive surgery leads with 46% market share, supported by more than 38 million annual procedures worldwide. General surgery represents 39%, while other applications contribute 15%. The growing prevalence of robotic surgery, trauma care, and specialty procedures continues to support adoption across both product categories and application segments.

BY TYPE

Sponge: Sponge-based Gelfoam products account for approximately 72% of the market. These products can absorb up to 45 times their weight in blood and expand significantly after placement, enhancing hemostatic effectiveness. More than 68% of orthopedic surgeries utilizing gelatin hemostats employ sponge formats because of their ease of handling. Neurosurgical and cardiovascular procedures also rely heavily on sponge products due to their conformability and absorbability. Approximately 74% of hospital procurement departments identify sponge-based gelatin materials as standard inventory items. Their ability to liquefy within 4 to 6 weeks eliminates removal requirements and supports widespread adoption across operating rooms globally.

Powder: Powder-based Gelfoam products represent approximately 28% of the market and are increasingly used in minimally invasive surgeries. These formulations provide effective bleeding control in anatomical locations where sponge placement is challenging. More than 38 million minimally invasive procedures annually create substantial opportunities for powder products. Approximately 57% of laparoscopic surgeons report improved accessibility with powder-based hemostatic agents. Powder formulations are particularly valuable in hepatic, urological, and thoracic surgeries involving irregular tissue surfaces. Adoption has increased due to enhanced delivery systems and improved handling characteristics. Healthcare facilities performing robotic-assisted procedures frequently incorporate powder-based gelatin products within surgical protocols.

BY APPLICATION

Minimally Invasive Surgery: Minimally invasive surgery accounts for approximately 46% of the Gelfoam Market. More than 38 million such procedures occur annually worldwide. Bleeding management is critical in laparoscopic and robotic surgeries where visualization must remain unobstructed. Approximately 61% of surgeons performing minimally invasive procedures prefer absorbable hemostatic materials. Gelfoam products provide localized bleeding control without requiring additional surgical intervention. Increasing adoption of robotic systems, which surpassed 1.8 million procedures annually, further supports this segment. Product demand remains strong across gynecology, urology, thoracic surgery, and gastrointestinal procedures.

General Surgery: General surgery represents approximately 39% of market demand. More than 110 million general surgical procedures are conducted globally each year. Gelfoam products are commonly used in abdominal, colorectal, hernia, and soft tissue operations. Approximately 71% of surgical departments maintain routine access to absorbable gelatin hemostatic agents. The ability to control capillary, venous, and small arterial bleeding contributes to widespread use. Increased hospitalization rates and aging demographics continue supporting segment expansion across developed and emerging healthcare markets.

Other: Other applications account for approximately 15% of market demand and include neurosurgery, orthopedic surgery, cardiovascular surgery, dental surgery, and trauma care. Orthopedic procedures exceed 28 million annually, while neurosurgical interventions surpass 13 million cases worldwide. Approximately 16% of trauma surgeries require advanced hemostatic management techniques. Gelfoam products offer effective bleeding control in delicate anatomical environments and remain widely utilized across specialty disciplines. Growth in specialized surgical services continues supporting demand within this segment.

Gelfoam Market Regional Outlook

Download FREE Sample to learn more about this report.

The Gelfoam Market demonstrates strong regional variation based on healthcare infrastructure, surgical volumes, and adoption of advanced hemostatic technologies. North America leads with approximately 41% market share due to high procedural volumes and established hospital systems. Europe follows with 29%, supported by extensive public healthcare networks. Asia-Pacific accounts for 22%, driven by expanding healthcare access and growing surgical demand. Middle East & Africa contribute 8%, supported by increasing investments in healthcare modernization. Rising adoption of minimally invasive surgery and enhanced bleeding management practices continue supporting market development across all regions.

NORTH AMERICA

North America accounts for approximately 41% of the Gelfoam Market. The region performs more than 70 million surgical procedures annually, creating substantial demand for absorbable hemostatic products. The United States represents the dominant market, supported by over 6,100 hospitals and nearly 9,300 ambulatory surgical centers. Approximately 79% of healthcare facilities utilize gelatin-based hemostatic products in selected procedures. Orthopedic surgeries exceed 7 million annual cases in North America, while cardiovascular interventions account for more than 2 million procedures. Gelfoam products remain widely adopted due to their ability to absorb up to 45 times their weight in blood. More than 61% of minimally invasive surgeries performed in the region involve absorbable hemostatic agents. The region also benefits from high adoption of robotic-assisted procedures, which surpassed 1 million annual cases. Healthcare spending on advanced surgical technologies continues increasing, supporting utilization of premium hemostatic products. Strong regulatory standards and widespread surgeon familiarity with gelatin-based materials reinforce North America's leadership position in the Gelfoam Market.

EUROPE

Europe represents approximately 29% of global Gelfoam demand. The region conducts more than 60 million surgical procedures annually across public and private healthcare systems. Germany, France, Italy, and the United Kingdom collectively account for over 58% of European surgical activity. Approximately 73% of major hospitals maintain standardized protocols involving absorbable hemostatic products. Minimally invasive surgeries exceed 11 million procedures annually throughout Europe. Gelfoam adoption remains particularly strong in orthopedic, neurosurgical, and cardiovascular applications. Approximately 67% of surgeons prefer absorbable materials that eliminate postoperative removal requirements.  The region benefits from advanced healthcare infrastructure, with more than 15,000 hospitals providing surgical services. Aging populations continue increasing procedural demand, as individuals aged 65 years and above account for over 21% of the population. Investments in robotic surgery systems and operating room modernization further support Gelfoam utilization across European healthcare facilities.

ASIA-PACIFIC

Asia-Pacific accounts for approximately 22% of the Gelfoam Market and remains a rapidly expanding region. The region performs more than 120 million surgeries annually, supported by a population exceeding 4.8 billion individuals. China, Japan, India, and South Korea collectively contribute over 70% of regional demand. Healthcare infrastructure expansion remains a key growth factor. More than 25,000 new hospital beds are added annually across major economies. Approximately 54% of newly established tertiary care facilities incorporate advanced surgical bleeding-management products into procurement programs. Rising awareness regarding surgical outcomes has increased utilization of absorbable hemostatic agents. Minimally invasive procedures exceed 14 million annual cases in Asia-Pacific. The region is also witnessing growing adoption of robotic-assisted surgery platforms. Governments continue investing in healthcare modernization, while increasing access to surgical services supports demand for Gelfoam products. Expanding medical tourism activity further contributes to regional market development.

MIDDLE EAST & AFRICA

The Middle East & Africa account for approximately 8% of the Gelfoam Market. Healthcare investments have increased significantly, supporting expansion of surgical capacity across the region. More than 4 million major surgical procedures are performed annually, with growing demand for advanced hemostatic products. Countries in the Gulf region have expanded healthcare infrastructure through the addition of more than 20,000 hospital beds during recent years. Approximately 48% of tertiary care hospitals utilize absorbable gelatin-based hemostatic agents during specialized surgeries. Trauma care remains an important application area due to increasing emergency treatment requirements. Minimally invasive surgery adoption is expanding steadily, particularly in urban healthcare centers. More than 500 robotic surgical systems are operational across key regional markets. Healthcare modernization programs, increasing surgeon training initiatives, and growing access to advanced medical technologies continue supporting demand for Gelfoam products throughout the Middle East and Africa.

List of Top Gelfoam Market Companies

• Johnson and Johnson
• Gelita
• Pfizer
• Baxter
• Ferrosan Medical Devices
• B Braun
• Equimedical

List of Top 2 Companies Market Share

• Johnson and Johnson: Approximately 34% market share, supported by extensive global distribution and strong surgical hemostatic product adoption.
• Baxter: Approximately 21% market share, driven by a broad portfolio of surgical bleeding-control solutions and strong hospital penetration.

Investment Analysis and Opportunities

The Gelfoam Market continues attracting investment due to rising surgical volumes exceeding 320 million procedures annually. Hospitals account for approximately 72% of product consumption, creating stable demand for absorbable hemostatic materials. Investments are increasingly focused on manufacturing expansion, sterilization technologies, and advanced gelatin processing capabilities. Minimally invasive surgery represents a significant opportunity, with more than 38 million annual procedures requiring precise bleeding control. Powder-based formulations have become a major investment focus because they address complex surgical environments inaccessible to traditional sponge products. Approximately 46% of total market demand originates from minimally invasive applications.

Emerging economies provide substantial growth opportunities. More than 45% of newly established surgical facilities are located in developing healthcare markets. Healthcare infrastructure modernization programs continue increasing demand for advanced hemostatic technologies. Manufacturers are also investing in combination products integrating gelatin matrices with biologically active agents. Enhanced sterilization systems achieving effectiveness levels above 99.9999% remain a key area of capital expenditure. Strategic partnerships with hospitals and surgical centers further support long-term market expansion opportunities.

New Product Development

Innovation within the Gelfoam Market is focused on improving hemostatic performance, absorption characteristics, and surgeon usability. Modern gelatin-based products can absorb up to 45 times their weight in fluid while maintaining structural integrity during critical surgical stages. Manufacturers are developing next-generation formulations designed to improve tissue conformity by more than 30%.

Powder-based delivery systems represent a major innovation area. These products enable access to difficult anatomical locations and are increasingly utilized in robotic-assisted procedures exceeding 1.8 million annual cases globally. Approximately 57% of surgeons performing minimally invasive surgeries report preference for advanced powder formulations. Combination hemostatic products integrating gelatin matrices with thrombin components have demonstrated enhanced bleeding control performance. New manufacturing technologies focus on pore uniformity and improved absorption rates. Product sterilization improvements support microbial reduction levels exceeding 99.9999%. Manufacturers are also developing specialized formats tailored to neurosurgery, cardiovascular surgery, and orthopedic procedures. Enhanced packaging systems and ready-to-use configurations continue improving operating room efficiency and supporting broader adoption of advanced Gelfoam products.

Five Recent Developments

• In 2023, major manufacturers expanded absorbable gelatin hemostatic production capacity by approximately 18% to support growing surgical demand.
• In 2023, advanced powder-based gelatin formulations achieved adoption growth of 14% within minimally invasive surgical applications.
• In 2024, combination gelatin-thrombin hemostatic products increased utilization by 21% across specialized surgical procedures.
• In 2024, manufacturers introduced sterilization improvements achieving microbial reduction effectiveness exceeding 99.9999%.
• In 2025, robotic-assisted surgery applications utilizing absorbable gelatin hemostats increased by 17% compared with previous deployment levels.

Report Coverage of Gelfoam Market

The report provides comprehensive analysis of the Gelfoam Market across product categories, applications, regional trends, and competitive dynamics. Coverage includes sponge and powder formulations, with sponge products accounting for approximately 72% of overall demand. Product performance assessment evaluates absorption capacity, handling characteristics, biodegradability, and surgical effectiveness. Application analysis covers minimally invasive surgery, general surgery, and specialty procedures. Minimally invasive surgery represents 46% of market demand due to increasing procedural volumes exceeding 38 million cases annually. General surgery contributes 39%, supported by widespread adoption across hospitals and ambulatory centers.

Regional evaluation includes North America, Europe, Asia-Pacific, and Middle East & Africa. North America leads with 41% market share, while Europe accounts for 29%. The report assesses healthcare infrastructure development, surgical procedure volumes, hospital adoption rates, and technological advancements influencing market demand. Competitive analysis reviews leading manufacturers, product portfolios, innovation strategies, and distribution networks. The report also examines investment trends, manufacturing capabilities, sterilization technologies, and regulatory requirements. Additional coverage includes emerging opportunities associated with robotic-assisted surgery, advanced hemostatic formulations, specialty surgical applications, and healthcare modernization initiatives driving future demand for Gelfoam products worldwide.